课题基金 / 基金详情

基于Adam8介导的胞外微环境病变研究体外培育牛黄改善胆汁淤积性肝损伤的机制

批准号:
82104507
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
向东
依托单位:
学科分类:
中药消化与呼吸药理
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
向东

项目摘要

结项摘要

相似基金

相关文献

中文摘要
胆汁淤积性肝损伤(CLI)广泛存在于各种急、慢性肝病中,中医将其归属于“黄疸”范畴。CLI发病机制复杂,传统聚焦于改善肝细胞内胆汁酸失衡的药物疗效欠佳,调控胞外微环境病变成为近年来的研究热点。我们前期发现:CLI机体内疏水性胆汁酸累积可上调肝细胞Adam8的表达并与胞外炎症、增生和纤维化病变有关,中药体外培育牛黄(CBS)可下调Adam8而逆转上述异常。国内外研究显示Adam8是一种膜脱落酶,可通过向胞外域脱落相关底物参与细胞间信号交互。据此假说:CLI发病中,疏水性胆汁酸上调肝细胞Adam8并介导底物向胞外域脱落,促进胞外微环境炎症、增生和纤维化病变,而CBS可通过干预Adam8显著逆转。本课题拟从整体、细胞和分子水平,运用基因功能获得与缺失、血清药理学、血清药物化学等技术,阐明CBS干预Adam8脱落底物缓解CLI胞外微环境病变的作用机制及物质基础,为CLI提供新的治疗药物和靶点。
英文摘要
Cholestatic liver injury (CLI) widely exists in all kinds of acute and chronic liver diseases, which belongs to "jaundice" in Traditional Chinese Medicine. The pathogenesis of CLI is complicated, and drugs traditionally focusing on bile acid homeostasis in hepatocytes are not effective. The regulation of extracellular microenvironment has become a hotspot in recent years. We previously found that the accumulation of hydrophobic bile acids induced the upregulation of Adam8 in hepatocytes, which was correlated to extracellular inflammation, proliferation, and fibrosis in CLI, while Calculus Bovis Sativus (CBS) could downregulate Adam8 expression and significantly reverse the above abnormalities. Domestic and foreign studies have shown that Adam8 is a membrane shedding enzyme which participates in intercellular signal interaction by ectodomain shedding of related substrates. Based on these, we hypothesized that hydrophobic bile acids upregulate the expression of Adam8 in hepatocytes and mediate the ectodomain shedding of substrates, which promote inflammation, proliferation and fibrosis of the extracellular microenvironment, while CBS can significantly reverse these by intervening the expression of Adam8. This study intends to use techniques, such as overexpression- and knockout-genes, serum pharmacology, and serum medicinal chemistry, to clarify the mechanism and material basis of CBS in improving the extracellular microenvironmental pathology of CLI by intervening Adam8-mediated shedding from the animal, cellular and molecular levels, which will provide new therapeutic drugs and targets for CLI.
胆汁淤积性肝损伤(CLI)广泛存在于各种急、慢性肝病中,中医将其归属于“黄疸”范畴。CLI发病率高且难以治疗,迫切需求寻找有效的治疗靶点和药物。本研究通过建立胆管结扎诱导的CLI动物模型,明确体外培育牛黄(CBS)和Adam8基因敲除具有显著改善小鼠肝生化指标、肝脏病理改变、胆管增生、炎性反应和纤维化病变的作用,而肝脏过表达Adam8则明显逆转了CBS的改善作用;通过构建胆汁酸诱导的肝细胞损伤模型,发现CBS含药血清可显著改善疏水性毒性胆汁酸鹅去氧胆酸(CDCA)和石胆酸(LCA)诱导的肝细胞损伤、炎症因子释放和细胞凋亡,而过表达Adam8则逆转CBS这一作用;通过细胞因子芯片和酶联免疫吸附法(ELISA)检测证实Vegf是Adam8胞外脱落的关键底物,且Vegf具有促进胆汁淤积下胆管细胞增殖、库否细胞炎症和星状细胞纤维化的作用,CBS可通过下调Adam8的表达而阻断其胞外脱落Vegf;通过建立液相色谱串联质谱的分析测定方法,我们测定发现CBS含有42种胆汁酸成分,可检测入血成分27种,其中浓度较高的胆汁酸为猪去氧胆酸(HDCA)、脱氧胆酸(DCA)、胆酸(CA)、异胆酸(iso-CA)、7-酮去氧胆酸(7-KDCA),体外实验表明iso-CA、熊胆酸(UCA)可能是CBS干预Adam8表达的关键药效物质;通过网络药理学分析入血成分靶点与CLI疾病靶点的关联性,发现基因调控、细胞粘附和凋亡可能是CBS介导Adam8改善CLI的关键机制。本研究阐明了CBS干预Adam8脱落关键底物Vegf缓解CLI胞外微环境病变的作用机制及物质基础,可为未来CLI的治疗提供新的药物和干预靶点。
国内基金
海外基金